Foghorn Therapeutics Taps Biotech Veteran Ryan Maynard as CFO

Foghorn Therapeutics has appointed Ryan Maynard, the former financial chief of Cara Therapeutics, as its new Chief Financial Officer. Maynard brings more than 25 years of executive experience across the biopharmaceutical and healthcare technology sectors to the clinical-stage firm as it scales its operations.

February 23, 2026, 03:46 PM 0 0

Ryan Maynard joins the company with a deep background in healthcare technology and drug development. He previously held the CFO mantle at Rigel Pharmaceuticals, LetsGetChecked Inc., and Blade Therapeutics. Foghorn CEO Adrian Gottschalk characterized the hire as a move to strengthen the firm's operational leadership, stating that Maynard’s experience in scaling organizations will be essential to the company’s growth.

Compensation and Incentives

Under the terms of his employment, Maynard will receive an annual base salary of $510,000 and a $90,000 signing bonus. The compensation package also includes eligibility for an annual performance-based bonus set at 40% of his base salary, in addition to a stock option award, according to the company's disclosure.

The appointment of Ryan Maynard marks a significant addition to the Foghorn Therapeutics executive team as the firm continues to navigate the clinical development landscape. His career has been defined by managing financial operations for diverse biotech entities, making him a strategic fit for the company's current trajectory.

When reusing this material a link to Money Talk is required.